Abstract
Abstract(1) BackgroundThe morbidity and mortality rate of Digestive System Cancers (DSC) continue to threaten human lives and health. Nuclear factor erythroid 2-like protein 3 (NFE2L3) is associated with the development, growth, and progression of multiple cancers. Nevertheless, the clinical value and underlying mechanisms of NFE2L3 in DSC remains unknown. This study aimed to clarify the possibilities of NFE2L3 as a novel biomarker in DSC.(2) MethodsWe obtained the data of NFE2L3 in cancers from database to evaluate the expression level and clinical value of NFE2L3 in DSC, and to explore underlying mechanism and biological functions of NFE2L3 in DSC.(3) ResultsNFE2L3 expression is up-regulated in DSC and have both prognostic and diagnostic value. NFE2L3 contributes to oncogenesis through a variety of mechanisms. In vitro experiment showed that NFE2L3 stimulated the proliferation and migration ability of gastric cancer cells.(4) ConclusionOur study confirms the clinical applicability of NFE2L3 as a promising biomarker for DSC.
Publisher
Cold Spring Harbor Laboratory